Reason for request
Assessment of change of dose permitting use in children aged between 2 and 16.
Clinical Benefit
| Substantial |
The clinical benefit provided by DUROGESIC in children is substantial. |
Clinical Added Value
| Comments without ASMR value |
DUROGESIC has previously been recognised by the Transparency Committee as providing actual benefit in adults, and it provides the same benefit for children over 2. |
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
QZw85JFRGnGBAYek
